Delcath Sys Stock Price, News & Analysis

Delcath Systems (Nasdaq: DCTH) granted equity inducements to six new employees who started in September or October 2025 under its 2023 Inducement Plan.

The awards grant the right to purchase 62,500 shares via stock options granted on October 31, 2025 with an exercise price of $9.83 (the closing price that day). One‑third vests on the first anniversary; the remaining two‑thirds vest monthly over the next 24 months. Options have a 10‑year term and vest only with continued employment. Grants were made per Nasdaq Rule 5635(c)(4).

Delcath Systems (Nasdaq: DCTH) highlighted a University of Tubingen retrospective analysis (2005–2021) of 167 metastatic uveal melanoma patients with liver metastases that links early liver-directed therapy, including chemosaturation/percutaneous hepatic perfusion (PHP), to improved long-term outcomes.

Key metrics: 33 long-term survivors (20%); 82% of long-term survivors had liver-directed therapy as first-line metastatic treatment; 93% disease control rate with first-line liver-specific therapy vs 63% with first-line systemic therapy; 52% received PHP with median overall survival 37.35 months and median progression-free survival 10.28 months; PHP as first liver-directed therapy showed 100% disease control and 69% partial response. The analysis used Delcath CHEMOSAT technology (same as FDA-approved HEPZATO KIT).

Delcath Systems (Nasdaq: DCTH) said management will attend two investor conferences in New York in November 2025: the Craig-Hallum Alpha Select Conference on November 18, 2025 and the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025. The company focuses on interventional oncology and therapies for primary and metastatic liver cancers.

Delcath Systems (Nasdaq: DCTH) reported third quarter 2025 results: $20.6M total revenue, including $19.3M HEPZATO kit sales and $1.3M CHEMOSAT sales. Gross margin was 87%, net income was $0.8M, and non-GAAP adjusted EBITDA was $5.3M. Cash and investments totaled $88.9M with no debt as of September 30, 2025.

Operational highlights include 25 active U.S. centers, first patient dosed in the global Phase 2 HEPZATO trial for liver-dominant metastatic colorectal cancer, and presentation of positive Phase 2 CHOPIN investigator-initiated results showing improved one-year PFS for CHEMOSAT plus ipilimumab/nivolumab. Full-year 2025 revenue guidance: $83–$85M (about 150% volume increase vs 2024) with continued positive adjusted EBITDA and cashflow each quarter.

Delcath Systems (Nasdaq: DCTH) will host a conference call on November 4, 2025 at 8:30 AM Eastern Time to discuss results for the third quarter ended September 30, 2025. Participants should dial in 5–10 minutes early using the provided toll-free or international numbers or join the live webcast. A replay of the webinar will be available shortly after the call and archived on the company website.

Delcath Systems (NASDAQ: DCTH) reported preliminary Q3 2025 results and updated 2025 guidance. Q3 total CHEMOSAT and HEPZATO KIT revenue was approximately $20.5 million (HEPZATO $19.2M; CHEMOSAT $1.3M). Q3 gross margin is expected to be 87%, net income $0.8 million, adjusted EBITDA $5.3 million, and operating cashflow roughly $4.8 million. Cash, cash equivalents and short-term investments were approximately $88.9 million with no debt as of September 30, 2025.

Full-year 2025 revenue guidance is $83 million to $85 million, reflecting an approximate 150% treatment volume increase versus 2024. Management cites NDRA discounts and summer seasonality for the Q3 decline and will discuss Phase 2 CHOPIN trial results on a conference call on October 20, 2025.

Delcath Systems (NASDAQ: DCTH) announced results from the investigator-initiated Phase 2 CHOPIN trial in metastatic uveal melanoma showing that adding ipilimumab and nivolumab to CHEMOSAT/HDS percutaneous hepatic perfusion (PHP) met the primary endpoint of one-year progression-free survival.

Key results: one-year PFS 54.7% (combination) vs 15.8% (PHP); median PFS 12.8 vs 8.3 months; HR 0.34 (P<0.001). One-year OS similar (~82%); median OS 23.1 vs 19.6 months; OS HR 0.39 (P=0.006). Best overall response 76.3% vs 39.5% (P<0.001). Grade ≥3 treatment-related AEs higher in combination (81.6% vs 40.5%).

Delcath Systems (NASDAQ:DCTH), focused on liver cancer treatments, announced that results from their investigator-initiated CHOPIN Phase 2 trial will be presented at the ESMO 2025 Annual Congress. The presentation will be delivered by Principal Investigator Dr. Ellen Kapiteijn from Leiden University Medical Center.

The trial evaluates the combination of systemic immunotherapy (ipilimumab and nivolumab) with Delcath's CHEMOSAT® Hepatic Delivery System for treating metastatic uveal melanoma patients. The presentation is scheduled for October 18, 2025, at 3:20 p.m. CET, and the poster will be available on Delcath's investor relations website following the ESMO embargo lift.

Delcath Systems (Nasdaq: DCTH), an interventional oncology company, has granted equity inducement awards to three new employees who joined in June 2025. The awards consist of options to purchase 78,000 shares of common stock at an exercise price of $11.02 per share, matching the closing price on August 29, 2025.

The options, granted under Delcath's 2023 Inducement Plan, will vest over three years, with one-third vesting after the first year and the remainder vesting monthly over the following 24 months. The ten-year term options were awarded in compliance with Nasdaq Listing Rule 5635(c)(4).